The Food and Drug Administration (FDA) has approved PARI’s eRapid Nebulizer System (eRapid), the first electronic nebulizer to deliver Pulmozyme (dornase alfa [recombinant human DNase]; Genentech) for ...
RICHMOND, Va., Jan. 26, 2015 /PRNewswire/ -- The eRapid Nebulizer System (eRapid) from PARI has been approved as the first electronic nebulizer by the Food and Drug Administration to deliver Genentech ...
The US Food and Drug Administration (FDA) has approved the eRapid nebulizer system (PARI), the first electronic nebulizer to deliver dornase alfa (Pulmozyme, Genentech) for the treatment of cystic ...
Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme. A ...
More than 70,000 people worldwide are suffering from cystic fibrosis, suggests the Cystic Fibrosis Foundation Patient Registry. Approximately 1,000 new cases are diagnosed each year in the United ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Electronic patient self-Reporting of Adverse ...
Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102 A randomized controlled trial ...
(BOSTON) -- Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that its eRapid technology has been licensed to The iQ Group Global for COVID-19 diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results